If you have trouble viewing the newsletter, please click here.
td height="25" align="center">If you don't want to recieve any further ESOP Newsletters, please click to unsubscribe.

ESOP Certificate Courses, Aseptic Working e-Training Program & Practice

Dear Colleagues,

I would like to invite you to ESOP Certificate Course "Aseptic Working e-Training Program & Practice".

Please contact via membershipservice@esop.li. First Part will be at 14.10.2015 20:00 CET European Society of Oncology Pharmacy will be conducting a series of trainings for this year entitled “ESOP Certificate Courses, Aseptic Working e-Training Program & Practice”. The target participants are our own members. In this regard, may we invite you to attend our free course.

The series of trainings will be held directly via Internet. First part will be at 14th October 2015 20:00 CET. Maximum capacity of the class is 100. After registration we will send you an invitation link by email. When you open the email, you will find a link. Please click on it and connect directly Adobe Acrobat based e-learning software. You don’t need extra software etc. You can see the speakers on-line; you can ask your question directly. Our program will have 5 parts. Four of them will be held via Internet, the last one which includes workshops will be at 3rd European Congress of Oncology Pharmacy in Dubrovnik/Croatia, 19th May 2016. Please inform us with mail if you will attend the congress. This information is important because in case of the applications exceed 100 people, priority will be given to conference participants.

This course is free to our members. The ESOP as federation is based on national groups or associations for oncology pharmacy. Because of that, all applications will be check by your country’s national group or association.

With kind regards
Ahmet Bosnak
Project-Chair Internal Communication and Internet Presence

Download the information sheet »

Long-term body retention of platinum based anticancer drugs

Chemotherapy besides its side effects in patients that are receiving it may also cause potential danger to patient beloved ones and medical personnel. Why is so?

The medications used in chemotherapy commonly have very narrow therapeutic index and highly variable pharmacokinetics which makes them highly toxic. These medications require special storage conditions and safe handling.

Another problem occurring in chemotherapy is retention of these drugs in the body for years after chemotherapy and their high concentration in body fluids. Platinum based anticancer drugs; cisplatin and oxaliplatin are commonly used chemotherapy drugs in treatment of various malignant diseases.  Hohnloser and associates data indicate that even 8 years after cisplatin-based chemotherapy 500 times elevated urinary and serum platinum levels can be measured in patients suffered from testicular cancer.1 Gerl and Schierl reported that platinum can be found 5.3 to 16.8 years after cisplatin-based chemotherapy in 100 – 1000 times higher concentrations in urine and serum of treated patients compared to unexposed controls.2 Similar results were published by Gietema and associates. Circulating platinum was still detectable in plasma up to 20 years after administration of cisplatin-based chemotherapy.3 Platinum plasma levels were more than 30-fold higher in patients treated 8 to 75 months before with cisplatin or oxaliplatin than the mean plasma platinum level of unexposed controls.4

After administration of cisplatin in doses of 20 to 120 mg/m2 the concentrations of platinum are highest in liver, prostate, and kidney; somewhat lower in bladder, muscle, testicle, pancreas, and spleen; and lowest in bowel, adrenal, heart, lung, cerebrum, and cerebellum. Excretion of platinum into milk occurs but the results are inconsistent due to small number of cases.5

It is often underestimated care and safety of people surrounding patients on chemotherapy. Because of long retention of these drugs in the body of the patients it is of big importance to familiarize them on these facts, and advise them to adjust their behaviour and contact according to recommendations of clinical pharmacist on oncology ward.

Eugen Javor M.Pharm. Clinical pharmacy resident

Clinical pharmacists on oncology wards are experts in the medications used to treat and manage complications of cancer and its side effects. 

Therefore besides ensuring appropriate drug dosing, evaluation of medication history profiles, identifying side effects and drug interactions, the clinical pharmaciston oncology ward has also a big role in consulting patients with aim to ensure proper and safe use of medications.


  1. Hohnloser JH, Schierl R, Hasford B, Emmerich B. Cisplatin based chemotherapy in testicular cancer patients: long term platinum excretion and clinical effects. Eur J Med Res. 1996;1(11):509-14.
  2. Gerl A, Schierl R. Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer. ActaOncol. 2000;39(4):519-22.
  3. Gietema JA, Meinardi MT, Messerschmidt J, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet. 2000;355(9209):1075-6.
  4. Brouwers EE, Huitema AD, Beijnen JH, Schellens JH. Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC ClinPharmacol. 2008;8:7.
  5. Drugs.com [Internet]. Virginia: USA. Zyrtec Information from Drugs.com; c2000-15. Cisplatin; 2015 October [Cited 2015 Sep 2]; [about 4 screens]. Available from http://www.drugs.com/pro/cisplatin.html.

With kind regards
Marko Skelin

Project-Chair Publication